(Total Views: 615)
Posted On: 08/09/2021 1:32:10 PM
Post# of 148898
This is a really good point, it is one thing to put value from our perspective on Cytodyn and another from the acquirer's perspective. We do need to realize that the investors in that company will immediately ask who is this company and you paid how much?
This is why historically these deals have partnerships in advance of an all-out buy out. I think many don't realize that the headline buyouts started years earlier with non-majority partnerships. I see this as the path cytodyn will take. Once the news of the trial data, BTD, BLA and any other catalysts the stock price will make the jumps necessary to be not so far off of the normal multiple buy out offers. the current SP is not going to a $30-100/share buyout overnight.
This is why historically these deals have partnerships in advance of an all-out buy out. I think many don't realize that the headline buyouts started years earlier with non-majority partnerships. I see this as the path cytodyn will take. Once the news of the trial data, BTD, BLA and any other catalysts the stock price will make the jumps necessary to be not so far off of the normal multiple buy out offers. the current SP is not going to a $30-100/share buyout overnight.
(6)
(1)Scroll down for more posts ▼
